Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema. (17th February 2020)

• Record Type: Journal Article
• Authors: Couret, Chloé; Servant, Marion; Lebranchu, Pierre; Hamidou, Mohamed; Weber, Michel
• Is Part Of: Ocular immunology and inflammation. Volume 28:Number 2(2020)
• Page Start: 329
• Page End: 336
• Publication Date: 2020-02-17
• Subjects: Efficacy and safety -- interferon -- refractory macular edema -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1604001
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : The aim of this study was to further explore the efficacy and safety of interferon-α in refractory non-infectious inflammatory macular edema and to compare interferon-α2a and pegylated interferon-α2b. Methods : 34 patients with refractory non-infectious uveitic macular edemaunder interferon-α were retrospectively reviewed. Results : Mean baseline best-corrected visual acuityimproved from 0.55 logMar to 0.37 logMAR (P < 0.001) at month (M) 1 and 0.40 logMAR (P < 0.001) at M6. The mean baseline CMT decreased from 554 µm to 367 µm (P < 0.001) at M1 and 394 µm (P < 0.001) at M6. Clinical adverse effects (AEs) were observed in a third of patients, leading to treatment discontinuation because of frequent mild AEs and few severe AE. No statistically significant difference was found between both molecules. Conclusions : Anatomically and functionally, interferon-α was rapidly effective despite a low dosage regimen and no difference in efficacy and tolerance was observed between interferon-α2a and pegylated interferon-α2b.